Among them, proteins in the canonical cancer driver pathways, including WNT5A, epidermal growth factor receptor (EGFR), and AKT2, were up-regulated in tumors with CDH1 mutations, while the WNT inhibitor, LRP10, was down-regulated, suggesting that up-regulations of WNT, EGFR, and AKT pathways are operational in CDH1-mutated tumors (Fig. 4d). This evidence concerns the gene AKT2 and cancer.